SEC Form 4 · accession 0001437749-15-004677
HYPERION THERAPEUTICS INC · HPTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christine A Nash
Officer — SVP & Chief Commercial Officer
Period of report
Mar 9, 2015
Accepted (ET)
Mar 10, 2015 · 7:37 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001386858
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 9, 2015 | S | 5,650 | $29.32 | D | 23,253 | D | |
| Common Stock | Mar 9, 2015 | S | 2,800 | $30.00 | D | 20,453 | D | |
| Common Stock | Mar 10, 2015 | S | 1,450 | $30.10 | D | 19,003 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 15, 2014.
- F2The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions from $29.08-29.70. The reporting person undertakes to provide Hyperion Therapeutics, any security holder of Hyperion Therapeutics or the staff of the Securities and Exchange Commission, upon request, the full information regarding the number of shares sold at each price within the ranges set forth in footnotes (2) and (3) to this Form 4.
- F3The price set forth in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $30.00-30.33.